SecBot SecBot

Drug Price Transparency in Medicaid Act of 2023

H.R. 1613 Rep. Earl Carter (R-GA-1) In committee
Bill text PDF
  1. Introduced Mar 17
  2. Committee Mar 17
  3. Passed House Next
  4. Passed Senate Not yet
  5. To President Not yet
  6. Law Not yet
Where it stands
In committee, Mar 17, 2023Next: House vote
1314d ago Mar 24, 2023: Referred to the Subcommittee on Health.
Final votes
No roll callsNo recorded vote on this bill yet
Lobbying
6companies, 7 filings
Subscribe to see spend
Member trades
17trades in the last 90 days
Subscribe to see who
Who backs the bill and who pushes back Subscribe

Companies lobbying on this bill

6 companies
Companies by sector
Biotech & Pharma 3Consumer & Retail 2Financials 1
Search all 6 companies, their asks and price moves Subscribe

Summary

Drug Price Transparency in Medicaid Act of 2023

Full summary1 paragraphs

This bill requires pass-through pricing models, and prohibits spread-pricing, for payment arrangements with pharmacy benefit managers under Medicaid. The bill also extends funding for retail pharmacy surveys and requires additional information with respect to price concessions and survey participation to be made publicly available.

Library of Congress summary, Mar 17, 2023

Summary versions
  • Introduced in HouseMar 17, 2023

Official record from Congress.gov, the House Clerk and the Senate; lobbying from Lobbying Disclosure Act filings. Updated Oct 28, 2026.